EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics of Afatinib after Intravenous and Oral Administrations in Rats Using Validated UPLC MS/MS Assay

Alanood S Almurshedi iD, Mahasen A Radwan, Bushra Al Quadeib iD, Basmah Aldosari, Iman M Alfagih, Salma S Almarshidy

Journal of Chromatographic Science · 2024

DOI: 10.1093/chromsci/bmac110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chromatographic Science, 2024. Verfasst von Alanood S Almurshedi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, King Saud University, 12331 Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Researchers Supporting Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Afatinib is designated as the first-line management therapy for patients with advanced non-small cell lung cancer, and metastatic head and neck cancer. LC coupled to MS/MS can be utilised in therapeutic drug monitoring to ensure optimal use of Afatinib with the reduction of its possible adverse reactions. The aim of this investigation was to determine the pharmacokinetics of Afatinib in rats after single IV (2 mg/kg) and oral (8 mg/kg) doses. Therefore, a selective, sensitive and precise UPLC MS/MS assay thru electrospray ionisation basis with positive ionisation approach was established to measure Afatinib concentrations in the rat. The precision and accuracy of the developed assay method in the concentration range of 10–1000 ng/ml show no significant difference among inter- and-intra-day analysis (P > 0.05). Linearity was detected over the studied range with correlation coefficient, r > 0.995 (n = 6/day). The pharmacokinetics of Afatinib in the rat after a single IV dose showed a mean terminal half-life of 4.6 ± 0.97 h, and a mean clearance 480 ± 80 ml/h/kg. After PO administration, a short absorption phase with a mean Tmax of 1.3 ± 0.6 h with the highest concentration of 513.9 ± 281.1 ng/ml, and the lowest concentration detected after 24 h was 18.8 ± 10.7 ng/ml.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansRatsAnimalsTandem Mass SpectrometryAfatinibRats, Sprague-DawleyChromatography, High Pressure LiquidAdministration, OralReproducibility of Results

Stichwörter der Autor:innen

AfatinibNSCLCUPLC MS/MSbioavailabilitypharmacokineticsrats

Substanzen

Afatinib

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmacy, King Saud University, 12331 Riyadh, Saudi Arabia.
  • Department of Pharmacy Practice/Clinical Pharmacy, Faculty of Pharmacy, Egyptian Russian University, Cairo-Suez Road, 11829 Cairo, Egypt.

ORCID-Profile: Alanood S Almurshedi, Bushra Al Quadeib

Förderung

  • Researchers Supporting Project

Zitieren

APA

Almurshedi, A. S., Radwan, M. A., Al Quadeib, B., Aldosari, B., Alfagih, I. M., & Almarshidy, S. S. (2024). Pharmacokinetics of Afatinib after Intravenous and Oral Administrations in Rats Using Validated UPLC MS/MS Assay. Journal of Chromatographic Science. https://doi.org/10.1093/chromsci/bmac110

Vancouver

Almurshedi AS, Radwan MA, Al Quadeib B, Aldosari B, Alfagih IM, Almarshidy SS. Pharmacokinetics of Afatinib after Intravenous and Oral Administrations in Rats Using Validated UPLC MS/MS Assay. Journal of Chromatographic Science. 2024. doi:10.1093/chromsci/bmac110

BibTeX
@article{Almurshedi2024,
  author = {Almurshedi, Alanood S and Radwan, Mahasen A and Al Quadeib, Bushra and Aldosari, Basmah and Alfagih, Iman M and Almarshidy, Salma S},
  title = {Pharmacokinetics of Afatinib after Intravenous and Oral Administrations in Rats Using Validated UPLC MS/MS Assay},
  journal = {Journal of Chromatographic Science},
  year = {2024},
  doi = {10.1093/chromsci/bmac110}
}
Kostenlos starten →